VPC-70619
Based on 2 publication(s) in Google Scholar
VPC-70619 is a potent N-Myc inhibitor. VPC-70619 blocks the binding of the N-Myc-Max heterocomplex to the DNA E-box and exhibits potent inhibitory activity against N-Myc-dependent cell lines. VPC-70619 can partially reverse paclitaxel (HY-B0015) resistance in cells by reducing MYCN expression. VPC-70619 can be used for cancer research (e.g., neuroblastoma and thyroid cancer).
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 2361742-30-3
- Formula: C16H8ClF3N4O
- Molecular Weight:364.71
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Transcription Factor-Targeted Library
HY-L090
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cancer Stem Cells Compound Library
HY-L135
-
Mitochondrial Protection Compound Library
HY-L144
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) VPC-70619
More
Biological Activity
VPC-70619 (10 μM) exhibits an inhibition rate of 99.4% in IMR32 cells, while only 14.1% in HO15.19 cells[1].
VPC-70619 (1-10 μM) is shown to be highly stable with a T1/2 of 2310 min in In liver microsomes[1].
VPC-70619 upregulates the mRNA levels of MYCN, MDM2, and CRABP2, and downregulates TGM2 and INHBA, confirming its specific regulatory effect on the MYCN signaling pathway in SW1736-PTX and 8505C-PTX cells[2].
VPC-70619 (0.5-30 μM, 0-72 h) inhibits the proliferation, migration and aggressiveness of SW1736-PTX and 8505C-PTX cells, and the effect is enhanced when combined with Paclitaxel[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2361742-30-3
-
Appearance Solid
-
Molecular Weight 364.71
-
Formula C16H8ClF3N4O
-
Color Off-white to light yellow
-
SMILES
N#CC1=CC(C(F)(F)F)=C(C=C1)NNC(C2=CC=C(C(Cl)=C2)C#N)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation. [Abstract]2023 Mar 22;24(6):5993. PMID: 36983070 -
Solvent & Solubility
DMSO : ≥ 100 mg/mL (274.19 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ton AT, et al. Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer. Int J Mol Sci. 2022;23(5):2588. Published 2022 Feb 26. [Content Brief]
[2]. Molteni E, et al. GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation. Int J Mol Sci. 2023 Mar 22;24(6):5993. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7419 mL | 13.7095 mL | 27.4190 mL | 68.5476 mL |
| 5 mM | 0.5484 mL | 2.7419 mL | 5.4838 mL | 13.7095 mL | |
| 10 mM | 0.2742 mL | 1.3710 mL | 2.7419 mL | 6.8548 mL | |
| 15 mM | 0.1828 mL | 0.9140 mL | 1.8279 mL | 4.5698 mL | |
| 20 mM | 0.1371 mL | 0.6855 mL | 1.3710 mL | 3.4274 mL | |
| 25 mM | 0.1097 mL | 0.5484 mL | 1.0968 mL | 2.7419 mL | |
| 30 mM | 0.0914 mL | 0.4570 mL | 0.9140 mL | 2.2849 mL | |
| 40 mM | 0.0685 mL | 0.3427 mL | 0.6855 mL | 1.7137 mL | |
| 50 mM | 0.0548 mL | 0.2742 mL | 0.5484 mL | 1.3710 mL | |
| 60 mM | 0.0457 mL | 0.2285 mL | 0.4570 mL | 1.1425 mL | |
| 80 mM | 0.0343 mL | 0.1714 mL | 0.3427 mL | 0.8568 mL | |
| 100 mM | 0.0274 mL | 0.1371 mL | 0.2742 mL | 0.6855 mL |
Powered by Bioz